Onlife® - Quellennachweise und weiterführende Literatur
Sie erhalten hier eine Übersicht über Quellen und weiterführende Literatur zu den Inhaltsstoffen in OnLife und ihrer möglichen Wirkung bei Nervenschädigungen
Aus rechtlichen Gründen weisen wir darauf hin: Die Informationen, die bzgl. der Wirkungen der Nähr- und Inhaltsstoffe in Onlife® gegeben werden, wurden sorgfältig recherchiert und aus Studien erarbeitet. Sie dienen der Zusammenfassung wissenschaftlicher Erkenntnisse und nicht der Konstatierung einer entsprechenden Wirksamkeit des Produkts. Die Studienergebnisse können nachgelesen werden:
(1) Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010)
(2) Cocito D., Peci E., Ciaramitaro P., Merola A., Leonardo L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Research and Treatment. 2014
(3) Di Cesare Mannelli L., D‘Agostino G., Pacini A., et al. Palmitoylethanolamide is a disease- modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators of Inflammation. 2013
(4) Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, Esposito E, et al. Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS One. 2015;10
(5) Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U S A. 1995;92: 3376–80
(6) Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, Schena M, Tinivella M, Tiozzo E, Catalano MG, Pugliese M. et al. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr. 2012;108: 327–333
(7) Ghoreishi Z, Esfahani A, Djazayeri A, et al.: (2012) Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer 12:355
(8) Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002; 56:388–96.
(9) Hesselink: New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 2012, 5, 12-23
(10) Hesselink J. M.: Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. International Medical Case Reports Journal. 2013;6(1):49–53.
(11) Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor perox- isome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-9
(12) Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2007;31:12–26
(13) Park SB, Lin CS, Krishnan AV et al. Longterm neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16: 708–716
Postma TJ, Vermorken JB, Liefting AJ et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489–494
(14) Reyes-Gibby CC, Morrow PK, Buzdar A et al. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 2009; 10: 1146–1150
(15) Shapiro H. Could n-3 polyunsaturated fatty acids reduce pathological pain by direct actions on the nervous system? Prostaglandins, leukotrienes, and essential fatty acids. 2003;68(3):219–24
(16) Skaper SD, Facci GP. Mast cells, glia and neuroinflammation: partners in crime? Immunology. 2014;141: 314–27.
(17) Skaper S. D., Facci L., Fusco M., Della Valle M. F., Zusso M., Costa B., et al. (2014). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
(18) Truini A., Biasiotta A., Di Stefano G., et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS & Neurological Disorders – Drug Targets. 2011;10(8):916–920.
(19) Visioli F, Giordano E, Nicod NM, Davalos A. Molecular targets of omega 3 and conjugated linoleic Fatty acids - „micromanaging“ cellular response. Front Physiol. 2012; 3:42 Inflammopharmacology 22, 79–94.
(20) Zaiss et al.: Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO Oncol Res Treat, 2021; 44(11): 613-621.
Leitlinien
(21) J Clin Oncol. 2014 Jun 20;32(18):1941-67: Prevention and management of chemotherapy- induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.